Polaryx Therapeutics Gets FDA Fast Track Designations for Its Lead Drug Candidate

By Robb M. Stewart

Polaryx Therapeutics has now been granted fast track designation by the Food and Drug Administration for all four indications it is testing with its lead drug candidate.

The last FDA decision adds Polaryx's PLX-200 to the fast track program, which is designed to expedite the review of therapies intended to treat serious or life-threatening conditions with unmet medical need, for the treatment of juvenile neuronal ceroid lipofuscinosis, Krabbe disease, and Sandhoff disease.

The regulator in March gave fast track designation to PLX-200 for the treatment of late-infantile neuronal ceroid lipofuscinosis.

In premarket trading, Polaryx's shares were 5.1% higher at $5.99.

All four prospective indications are being studied in a Phase 2 basket trial. CLN2 disease, CLN3 disease, Krabbe disease, and Sandhoff disease are neurodegenerative conditions with limited or no disease-modifying treatment options, Polaryx said.

PLX-200 is an orally available compound comprised of gemfibrozil, which is an FDA-approved lipid regulating agent in the fibrate family that has only been approved in a capsule form for adult patients with very high elevations of serum triglyceride levels to decrease serum triglycerides and very low-density lipoprotein cholesterol and increase high density lipoprotein cholesterol.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

April 21, 2026 09:19 ET (13:19 GMT)